Evaluation Of The Efficacy And Safety Of Chemotherapy In Elderly Patients With Multiple Myeloma Under Different Frailty Scores

Objective:To compare the efficacy and safety of different chemotherapy regimens in elderly MM patients.Methods:The clinical data of elderly patients with MM were retrospectively analyzed,including age,treatment plan,efficacy,adverse reactions,and the ability of daily living score included in the frailty score,the activity of daily living scale and the Charlson comorbidity index.According to the scoring standard,the patients were divided into fit group,mediate fit group and frail group.Statistical analysis of the treatment efficiency and adverse event rates of different chemotherapy regimens for elderly MM with different physical conditions.Results:Among 70 patients,the effective rates of the fit group,the mediate fit group,and the frail group were 79.5%,81%,and 40%,and the effective rates of the double and triple groups were 54.5% and 89.3% in the fit patients,70% and 90.9% in mediate fit patients,42.9% and 33.3% in frail patients,the triple regimen in fit patients had obvious advantages,and the difference was statistically significant(P<0.05),while the efficacy in mediate patients and frail patients little difference.During the induction of bortezomib,the incidence of adverse reactions in the triple group(78.6%)was higher than that in the double group(67.9%),and the difference was not statistically significant(P>0.05).There was no significant difference in the overall survival rate of less than one year and MM patients with molecular genetic abnormalities among the groups.Conclusion:The therapeutic effect is related to the patient’s physical condition.For patients with healthy physique,the triple regimen should be used first.For patients with weak physical constitution,the chemotherapy regimen with low drug toxicity should be selected from the perspective of safety.